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ABSTRACT
Introduction: Rheumatoid arthritis (RA) fatigue is
distressing, leading to unmanageable physical and
cognitive exhaustion impacting on health, leisure and
work. Group cognitive–behavioural (CB) therapy
delivered by a clinical psychologist demonstrated large
improvements in fatigue impact. However, few
rheumatology teams include a clinical psychologist,
therefore, this study aims to examine whether
conventional rheumatology teams can reproduce similar
results, potentially widening intervention availability.
Methods and analysis: This is a multicentre,
randomised, controlled trial of a group CB intervention
for RA fatigue self-management, delivered by local
rheumatology clinical teams. 7 centres will each recruit
4 consecutive cohorts of 10–16 patients with RA
(fatigue severity ≥6/10). After consenting, patients will
have baseline assessments, then usual care (fatigue
self-management booklet, discussed for 5–6 min), then
be randomised into control (no action) or intervention
arms. The intervention, Reducing Arthritis Fatigue by
clinical Teams (RAFT) will be cofacilitated by two local
rheumatology clinicians (eg, nurse/occupational
therapist), who will have had brief training in CB
approaches, a RAFT manual and materials, and
delivered an observed practice course. Groups of 5–8
patients will attend 6×2 h sessions (weeks 1–6) and a
1 hr consolidation session (week 14) addressing
different self-management topics and behaviours. The
primary outcome is fatigue impact (26 weeks);
secondary outcomes are fatigue severity, coping and
multidimensional impact, quality of life, clinical and
mood status (to week 104). Statistical and health
economic analyses will follow a predetermined plan to
establish whether the intervention is clinically and cost-
effective. Effects of teaching CB skills to clinicians will
be evaluated qualitatively.
Ethics and dissemination: Approval was given by an
NHS Research Ethics Committee, and participants will
provide written informed consent. The copyrighted
RAFT package will be freely available. Findings will be
submitted to the National Institute for Health and Care
Excellence, Clinical Commissioning Groups and all UK
rheumatology departments.
Trial registration number: ISRCTN: 52709998;
Protocol v3 09.02.2015.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic
inﬂammatory condition causing synovitis in
multiple joints, pain, joint destruction and
disability.1 Life-long treatment is by secondary
care rheumatology teams, using medication
to control inﬂammation and multidisciplinary
interventions to reduce symptoms and maxi-
mise self-management.2 3 RA affects approxi-
mately 500 000 people in the UK,4 and
fatigue is present on most days for most
people, with >70% reporting levels similar to
Chronic Fatigue Syndrome.5 6 RA fatigue is
overwhelming physical exhaustion that
impacts on social and work activities, and has
cognitive and emotional elements: poor con-
centration, frustration and tearfulness.7 8
People with RA identify fatigue as the main
reason for work loss, which affects >60% of
working patients, with production loss
Strengths and limitations of this study
▪ A pragmatic study testing a cognitive-behavioural
intervention that could be delivered by the usual
care team.
▪ A seven-centre trial targeting a broad population,
thus, results likely to be widely generalisable.
▪ Patient impact is evaluated in a holistic fashion
(eg, including valued life activities) alongside
health economic evaluation.
▪ This pragmatic trial includes usual care through-
out; any medication changes have the potential
to alter fatigue and, therefore, the trial results
(if changes differ between arms).
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estimated at >£650 million.9–12 Fatigue predicts and
reduces quality of life, is as hard to cope with as pain;
patients rate fatigue as a top priority,13–16 and inter-
national consensus states it must be evaluated in all RA
clinical trials.17
Patients consider this unmanageable symptom as
ignored by clinicians,7 and systematic review shows bio-
logical agents for RA inﬂammation have only a small
effect on fatigue.18 RA fatigue is associated with inﬂam-
mation, pain, disability, sleep, depression and beliefs,19–21
implying complex, multicausal pathways comprising
differing combinations of variables.22 23 This highlights
the critical need for self-management interventions.
Systematic review of randomised controlled trials (RCTs)
of non-pharmacological interventions demonstrates mod-
erate but signiﬁcant effects of exercise, and of cognitive–
behavioural therapy (CBT) on RA fatigue.24
CBT helps patients understand the thoughts and feel-
ings that drive behaviours, and uses cognitive restructur-
ing to help them make behaviour changes.25 For
example, a belief that tasks must be done perfectly, and
feeling guilty if they are not, may drive episodes of exces-
sive activity, leading to episodes of enforced rest (‘boom
and bust’). In CBT, key self-management skills of
problem-solving and goal-setting can be enhanced by
sharing the learning process in groups with other
patients as role models (social cognition theory; SCT) to
increase self-efﬁcacy, or conﬁdence that you can do some-
thing.26 Systematic reviews conclude that rheumatology
self-management courses using CBT and/or SCT are
more effective than information alone.27 28 Three RCTs
using group education, individual CBT or group CBT
reported reduction in RA fatigue.29–31 However, fatigue
was never the primary aim, entry criteria did not include
fatigue and was selective (early disease, low disability,
high distress). As RA fatigue is commonplace, self-
management interventions should target the broad RA
population. Therefore, in 2007–2009, an RCT conducted
by this group using broad RA inclusion criteria and
fatigue ≥6/10, compared a group CBT fatigue self-
management programme with information alone.32
Group CBT improved fatigue impact (effect size 0.77),
severity and coping, disability, depression, sleep, helpless-
ness and self-efﬁcacy. The intervention was co-facilitated
by a clinical psychologist and pain management
Occupational Therapist (OT), and in the nested qualita-
tive study, patients spontaneously raised CBT elements as
key to its success.33 However, few rheumatology units have
clinical psychologists, thus, the programme cannot cur-
rently be routinely delivered in clinical practise. The
same issue arises for multiple sclerosis and other long-
term conditions (LTC) where CBT reduces fatigue.34
Thus, for LTC services, if the usual clinical teams could
deliver an effective cognitive–behavioural (CB) interven-
tion for fatigue, it could be embedded in usual care,
delivered by clinicians who routinely support patients
in self-management, and understand how fatigue inter-
acts with disease ﬂuctuations, pain and disability.
Self-management of LTCs and improving access to psy-
chological therapies are key government targets;35–37
while RA-speciﬁc guidelines by National Institute for
Health and Care Excellence (NICE)38 and other profes-
sional bodies2 3 recommend support for self-
management, fatigue, and use of CB therapies. A search
of RCT registration databases found no trials of CB inter-
ventions by the usual clinical team for RA fatigue.
The primary aim of this RCT is to assess whether
there is a clinically important difference in the impact
of fatigue between a group CB self-management course
for RA fatigue delivered by two members of the usual
clinical rheumatology team in addition to usual care;
compared to usual care alone (information booklet).
The secondary aims are to: (1) compare differences
between groups for fatigue severity, fatigue coping,
mood, sleep, helplessness, pain, disability, valued activ-
ities, quality of life, work, health service use, acceptability
and cost-effectiveness for the National Health Service
(NHS), patients and society; (2) evaluate and control
for potential demographical, psychological and clinical
predictors of fatigue change; (3) evaluate persistence of
effect over 2 years and (4) explore whether clinical
teams trained in CB approaches perceive any positive or
negative outcomes, particularly on their wider clinical
practise. Clinical rheumatology teams will be trained to
deliver Reducing Arthritis Fatigue by clinical Teams
(RAFT) using CB approaches, which is a manualised
version of the original CBT intervention.32
METHODS
Study design
To test generalisability for wide delivery across the NHS,
this RCT involves seven rheumatology units encompass-
ing large/small, academic/non-academic departments
in city/rural areas. Blinding of patients and clinicians is
not possible because of the need to engage patients in
making cognitive and behavioural changes. However,
outcomes are obtained using validated patient self-
report measures, and analysis will be performed blind to
treatment allocation.
Sample selection and recruitment procedures
Inclusion criteria are patients aged ≥18 years with a con-
ﬁrmed diagnosis of RA39 and fatigue severity ≥6/10 on a
numerical rating scale (NRS),40 which they consider per-
sistent or recurrent, thereby targeting a broad RA popu-
lation. Exclusion criteria are insufﬁcient English
language to participate in group discussions, lacking cap-
acity for informed consent or recent changes to major
RA medication (16 weeks) or glucocorticoids (6 weeks).
A research nurse in each centre will aim to approach
all patients with RA attending for outpatient appoint-
ments, and may send mailshots using departmental data-
bases. Interested patients will complete a screening
fatigue NRS, and other eligibility criteria will be
checked. If a patient is interested but not currently
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eligible, the nurse will rescreen them after 3–4 months.
The anonymised age, gender and fatigue NRS of those
who decline will be recorded.
The nurse will discuss the patient information sheet
with eligible patients and inform them of the dates for
the next CB course (highlighting that they may/may not
be randomised to receive it). Over a period of 2 years,
each centre will recruit four consecutive cohorts of
10–16 patients. Closure of recruitment to a cohort will
be agreed with RAFT’s central study team. The research
nurse will invite patients to attend for written consent,
baseline assessments and ‘usual care’. The visits will take
place over a 2-week period, and when all are completed,
that cohort will be randomised. Building each cohort
will take several months; therefore, to maintain engage-
ment, the nurse will call waiting patients monthly to
update them.
Randomisation and allocation concealment
The research nurse will give each patient the next
unique study identiﬁer (ID) immediately after written
consent. As patients are offered a choice of baseline visit
dates/times, it is unlikely that ID allocation can be inﬂu-
enced. Whenever a centre has completed the baseline
visits for a cohort of 10–16 participants, the central
RAFT Trial Manager will email the ID list to Bristol
Randomised Trials Collaboration (BRTC) who will
manage the computer-generated randomisation using
an access database. Randomisation will be stratiﬁed by
centre and within each centre, by cohort (cohorts 1–4).
Allocation will be 1:1, but in the event of an odd
number, the CB arm will receive the additional patient.
Upon receiving the arm allocations from Bristol, the
research nurse will inform the consented participants by
telephone, following guidelines to ensure a neutral con-
versation (ie, no implied potential beneﬁt from a CB
allocation), reminding participants they have already
received usual care at baseline.
Patients randomised to the CB course but who are
unable to attend the next course dates, will be offered a
subsequent course, with a new baseline evaluation. Any
changes to eligibility between screening and baseline
(eg, fatigue less severe, medication change) will be
noted for subgroup analysis, but the patient will proceed
to randomisation. This reﬂects the pragmatic nature of
delivering interventions to a population with recurrent
but ﬂuctuating fatigue.
Sample size
The baseline-adjusted effect size (0.77) for fatigue
impact found in the original trial of CBT delivered by a
clinical psychologist was 1.95 units (SD=2.7, 0–10 visual
analogue scale).32 The current RCT of CB approaches
delivered by rheumatology teams is powered to be able
to demonstrate an average effect size across all partici-
pating centres of 75% of this (1.46 units, effect size
0.54)—clinically important, as it would reduce the
number of patients falling below the fatigue criterion for
trial entry by one-third. There are no published data on
a minimal clinically important difference (MCID) for
RA fatigue impact, but MCID for RA fatigue severity is
0.82–1.12 (0–10 scale).41 At a power of 90% and two-
sided signiﬁcance of 0.05, this requires 73 patients/arm.
As we are interested in the average effect across all
centres, we expect no loss of power as a result of rando-
mising patients by site.42 43
There are two potential sources of clustering in the
intervention arm: CB group effects and centre/tutor
effects. In the original trial,32 the intraclass correlation
coefﬁcient (ICC) for the CBT group using the primary
outcome was an estimated <0.00 001. No data exist for
centre/tutor effects of CBT on RA fatigue, so we are
taking an ICC value of 0.01 for groups clustered within
centres.44 The resulting design effects increase the
required sample size to 75/arm.
In the original RCT32 most attrition occurred after
patients had completed their intervention, that is, loss to
questionnaire completion. To minimise this, the primary
outcome (fatigue impact, NRS) will be collected by tele-
phone by the central RAFT team, missing data returns
will be followed up, and patients who wish to withdraw
will be asked if they would provide just their fatigue
impact NRS. We anticipate obtaining 80% of primary
outcome data (26 weeks). Longer term attrition is
unknown, therefore, we have assumed 50% and a
planned capacity to recruit up to 150 patients/arm, to
maintain sufﬁcient power at 2 years. A pragmatic
approach to recruitment is needed to take account of
natural variations in group size. Therefore, a target of
seven centres, each running four CB courses with an
average of six participants/group (n=168 in CB arm)
provides contingency for some smaller groups.
Intervention, tutor training and supervision
Intervention: RAFT development followed the MRC
framework for complex interventions.45 RAFT is deliv-
ered to groups of 5–8 patients with RA, in 6×2 h sessions
(weeks 1–6) and a 1 h consolidation session (week 14).
Sessions are cofacilitated by two members of the
rheumatology team (eg, nurse, OT) who have been
trained in RAFT (tutors).
RAFT content encapsulates the complex conceptual
framework of RA fatigue,22 in which thoughts, feelings
and behaviours interact with disease processes and conse-
quences (eg, inﬂammation, disability), and personal
context (values, circumstances) to exacerbate or perpetu-
ate fatigue. The ﬁrst hour of each session is a whole-
group discussion facilitated by the tutors. After a 15 min
break, the tutors divide the group into two, allowing each
patient to discuss their goals within a smaller group.
Topics build on each other week by week (table 1).
Homework, activity diaries and goal setting are classic CB
approaches.25
Week 1 starts with discussions that validate fatigue
experiences and the struggle to self-manage. After
coffee, tutors draw ideas from patients on why they
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persist in boom and bust behaviours (eg, the rewards of
getting things done), and the discussion is steered
towards helping patients generate positive strategies for
energy management (eg, prioritising, pacing). This is
built on by the patients’ homework, which is to self-
monitor their activity, rest and fatigue patterns by colour-
ing in a daily activity/rest chart every hour for the week.
In week 2, the discussion explores personal priorities,
and moves into goal setting. Here, the small groups
review each person’s daily activity chart to understand
patterns of behaviour and their consequences (fatigue),
and each patient is encouraged to set personal short
and long-term goals, using their activity/rest chart to
help them identify potential behavioural changes (typic-
ally reducing boom and bust behaviours). These charts
are the focus of the small group discussions throughout
RAFT, and as they are completed each week they should
show an improving balance of rest/activity. Review of the
latest activity charts is related to sleep and rest (week 3),
which link to relaxation and stress (week 4), and
difﬁculty communicating their needs (week 5). The
skills introduced in weeks 1–5 are reviewed in week 6,
and tutors draw from patients how to deal with setbacks
(metaphor of being in a pit). The seventh session (week
14, after patients have been trying new behaviours for
8 weeks) reﬂects on self-management progress (meta-
phor of leaving a desert island), consolidates the skills
learnt, reﬂects on how those worked in the real world,
and helps patients set future goals.
In the case of unexpected tutor absence (eg, illness),
the remaining tutor will either deliver the session alone,
delay by 1 week, or ask another clinical team member to
attend as a supporter. This clinician will not deliver
course content, and the group will not split for goal
setting. If there is long-term tutor absence, a new tutor
will be trained. If a patient is unable to attend a session,
they will be invited to come early the next week for
tutors to explain key content that was missed.
Tutor training: The RAFT manual contains detailed
instructions for each of the seven sessions, including
Table 1 RAFT course design
Week First hour Supporting materials* Second hour
1 Course purpose and expectations
Ground rules:
Commitment, confidentiality, homework
Validating fatigue: Share and discuss
fatigue experiences (difference from
flare)
Self-management strategies, struggles
and difficulty of changing habits
H: Arthritis Research UK booklets
H: Setting our course (groups’
ideas)
Energy management Boom and
bust behaviour Rewards/pitfalls
of this Prioritise, pace, plan,
choicesH: Achieving balance
H: Activity cycling
T: Activity/rest diaries
2 What are your priorities for change,
to ↑QoL?
What are your drainers and energisers?
T: Wheel of life (priority areas) Goal setting (two groups)
Short-term/long-term goals
Use peer group for ideas
3 Self-sabotage on the course
Sleep and rest
Hours needed? Quality vs quantity
Sleep hygiene strategies
H: Best ways of self-sabotage
H: Getting a better night’s sleep
T: Sleep diary (if needed)
Goal-setting review
Successes/barriers
New goals
4 Stress and relaxation
Personal stressors, bodily reactions
Relaxation rationale and techniques
H: Effects of stress
H: Relaxation practice guide
T: Relaxation CD
Goal-setting review
Successes/barriers
New goals
5 Assertiveness and communication
Passive, manipulative, assertive?
Other people’s reactions to these?
Communicating your needs
M: Cartoon examples
H: Saying ‘No’
Goal-setting review
Successes/barriers
New goals
6 Review self-help tools
What have you learnt?
Review each topic
Dealing with setbacks—what could
you do?
Negative self-talk, automatic thoughts,
rumination
M: Fatigue pit: Falling in/digging
out
H: The pit; Coping with setbacks
Goal-setting review
Successes/barriers
New goals
14 Review last 8 weeks; skills; dealing with
setbacks; new goals
M: Islands: Was on Desert island
(passive) looking at the Mainland
(100% healthy, unrealistic). Now
on Adaptive Coping Island
(realistic)
*H, handouts; M, metaphor; RAFT, Reducing Arthritis Fatigue by clinical Teams; T, tools.
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the key points to be drawn from patients, sample conver-
sations, suggested timings, and all required materials
(handouts, metaphors, goal-setting records, activity
charts) with a clear indication of when and how they are
to be used. The seven pairs of tutors will be trained
together in Bristol over four consecutive days by the
psychologist (Ambler) and OT (Knops) who delivered
the original intervention,32 covering an introduction to
CB principles, self-efﬁcacy and managing groups, plus
practise in CB techniques of formulation (linking
thoughts, feelings and behaviours) and Socratic ques-
tioning (as opposed to didactic information giving).25 26
RAFT sessions will be discussed and practised in groups,
with input from patient partners, and observation and
feedback from trainers. To complete their training, tutor
pairs must deliver a practise course to patients not in the
RCT, observed by a trainer, with feedback and debrieﬁng
after each session.
Clinical supervision: The tutors are experienced
rheumatology clinicians, requiring only minimal clinical
supervision/support in using CB approaches. Tutors will
select one session in alternate courses for observation by
the psychologist or OT with feedback and debrieﬁng.
Telephone support will be available (psychologist).
Fidelity to RAFT (quality assurance): Fidelity will be moni-
tored in one session of every course in each centre. An
independent clinical psychologist will randomly select a
session, and using a template, record use of CB
approaches, adherence to session plans, use of RAFT
materials and any unhelpful delivery styles (eg, didactic
teaching). If ﬁdelity is weak, clinical supervision is given
for the next session, followed by a further independent
observation.
Usual care
The arthritis fatigue self-management booklet in
common use46 was developed from this group’s original
RCT.32 It contains information on all the RAFT topics, a
pull-out sample activity/rest chart to complete, and sug-
gests that patients ask their rheumatology team for
support with goal setting if necessary. This 32-page
Arthritis Research UK free booklet is routinely provided
by UK Rheumatology Units and discussed by nurses.
Usual care will be delivered to all patients at the base-
line visit after consent and assessment, but prior to ran-
domisation. The research nurse will spend 5–6 min
discussing the booklet, using a standardised discussion
guide, including that the booklet suggests patients might
wish to request support from the rheumatology team. To
minimise the risk of contamination between arms, the
local nurse specialist managing such requests will try to
not book a control patient in to see a clinician who is
also an intervention tutor. This may be unavoidable in
small teams, therefore, tutors will record any control
patient appointments for fatigue support, for use in the
analysis. Clinical care will continue as usual for both
groups throughout; any medication changes will be
recorded for potential subset analysis.
Outcome assessments
Outcomes will be measured at Weeks 0, 6, 26, 52, 78 and
104 using measures validated in RA (table 2). The
primary outcome is fatigue impact at 26 weeks, when
patients should have become skilled at self-management.
The 6-week assessment (posted 2 days after session 6) will
capture the intense support of the weekly sessions, while
weeks 52, 78 and 104 assessments will capture long-term
outcome with skills either embedded or forgotten. For
exploratory analysis of the week 14 consolidation session,
fatigue data alone will be collected at weeks 10 and 18.
Fatigue impact (primary outcome) and fatigue experi-
ences will be measured using the trio of Bristol RA
Fatigue NRS (impact, severity, coping) and multidimen-
sional questionnaire (BRAF-NRS, BRAF-MDQ).40 47
Other clinical, mood and quality of life variables, plus
cost-effectiveness, process, acceptability and feasibility
will be evaluated as described in table 2.48–59 The quali-
tative evaluation of the tutor experiences, will be by
focus group and/or one-to-one interviews with tutors
after their ﬁnal RAFT course.60 61 These will be con-
ducted by a researcher not involved in training, to
explore their experiences of RAFT training and delivery,
including barriers and facilitators.
Analysis plan
Quantitative analysis will be performed using Stata, blind
to allocated arm, and will follow the Statistical and
Health Economics Plan approved by the independent
Trial Steering and Data Management and Ethics
Committees (TSC, DMEC). To be deﬁned as having
received RAFT, a patient in the intervention arm must
have attended at least session 1. Data entry checks
against 100% of questionnaires will be made by two
researchers together.
Clinical status analysis: The primary intention-to-treat
analysis will involve between-arm comparisons for the
primary outcome fatigue impact (BRAF-NRS Impact) at
26 weeks, adjusted for baseline values. Analyses of covari-
ance (ANCOVA) will use multivariable linear regression
models and standardised effect sizes calculated (adjusted
mean difference divided by pooled baseline SD), with
>0.5 considered a clinically meaningful effect. Sensitivity
analyses will be conducted by (1) additional adjustment
for any variables displaying imbalance at baseline,
(2) ﬁtting multilevel mixed effects models to investigate
any clustering effect from delivery in groups and centres,
and (3) multiple imputation techniques to investigate the
impact of missing data, based on 20 imputed data sets,
with baseline fatigue severity, impact, pain and disease
activity added to the imputation model as variables pre-
dictive of missingness.62 Secondary outcomes will be ana-
lysed in the same way, including analysis of the four
BRAF-MDQ fatigue subscales, and preliminary multivari-
able analysis of different attendance rates/patterns.
Further analyses using repeated measures mixed
effects ANCOVA models will examine the effect of inter-
ventions over time by including up to four follow-up
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scores (26, 52, 78, 104 weeks) for the primary outcome,
adjusting for baseline scores. Convergence/divergence
between trial arms over time will be investigated by
including appropriate interaction terms in the model.
Clustering effects will be investigated by including CB
group and centre IDs as additional levels. We will
examine (and if necessary, adjust for) possible differ-
ences between arms for RA medication changes. Where
numbers allow, we will explore coefﬁcients of predictors
of outcome.
Cost effectiveness analysis: Actual expenses of training
and delivery will be recorded. Unit costs for NHS staff
time for training and intervention delivery will be based
on national estimates and costs of medications; commu-
nity, primary and secondary care during follow-up will
be based on national tariffs,63–65 supplemented by
micro-costing or local estimates. Productivity costs due to
RA and fatigue will be estimated based on average
weekly earnings stratiﬁed by age.66 Resource use will be
combined with unit costs to estimate the incremental
cost or savings of the group CB programme over the
2-year period. The primary analysis will be from the soci-
etal perspective, including productivity costs. Secondary
analyses will restrict the perspective to NHS and per-
sonal social services costs.
EQ-5D-5L utility scores will be used to estimate Quality
Adjusted Life Years (QALYs), adjusting for any baseline
imbalances.67 Missing data on costs or QALYs will be
multiply imputed. Costs and outcomes during the
second year will be discounted in line with NICE guid-
ance.68 Cost and QALY data will be combined to calcu-
late an incremental cost-effectiveness ratio (ICER) and
net monetary beneﬁt (INMB) statistic,69 which will indi-
cate whether the group CB programme is cost-effective
compared with NICE thresholds of £20 000–£30 000 per
QALY gained. Uncertainty in the point estimate of cost
per QALY will be quantiﬁed by using bootstrapping
methods to calculate CIs around the ICER and INMB.
The probability that the group CB programme is cost-
effective will be depicted using a cost-effectiveness
Table 2 Outcome measurement
Outcome Scale (weeks 0, 6, 26, 52, 78, 104)
Clinical status and quality of life
Fatigue impact* Bristol RA Fatigue NRS Impact (BRAF-NRS)40 47
Fatigue severity* Bristol RA Fatigue NRS Severity (BRAF-NRS)40 47
Fatigue coping* Bristol RA Fatigue NRS Coping (BRAF-NRS)40 47
Fatigue overall and
subdimensions*
Bristol RA Fatigue Multi-Dimensional Questionnaire (BRAF-MDQ)40 47
Mood Hospital Anxiety and Depression scale48
Pain Visual analogue scale
Quality of life EQ-5D-5L;49 Global question from Arthritis Impact Measurement Scale50
Sleep quality Single question from Pittsburgh Sleep Quality Index51
Leisure activities Discretionary activity subscale of Valued Life Activities scale52
Social engagement Increased seeking of social support (unvalidated question, weeks 52, 104)
Disability Modified Health Assessment Questionnaire54
Disease activity DAS2855† Protein, Patient global opinion (VAS)Painful joints and swollen joints (clinician assessed);
C-Reactive
Disease activity PDAS256 Patient Self-report Disease Activity Score (PDAS2)56
Cost effectiveness
Utility scores EQ-5D-5L;49 Work Productivity and Activity Impairment scale57
Costs—staff (tutors, trainers) Time logs, travel forms, materials used (for training, practice and intervention courses);
group sizes
Costs—NHS primary care Patient questionnaires for medications, visits (excluding monthly blood monitoring for
RA drugs)
Costs—NHS secondary care In/outpatient episodes for rheumatology and orthopaedics, hospital transport (all via
hospital computer)
Costs – patients Patient questionnaires for travel related to healthcare, plus RAFT and sick leave where
appropriate
Processes for behaviour change
Helplessness, Self-efficacy Arthritis Helplessness Index58 and RA Self-Efficacy scale59
Acceptability and feasibility
RAFT and usual care (booklet) Satisfaction (unvalidated question) Week 26 only
RAFT Recommending the course to others (unvalidated question) Week 26 only
Feasibility of NHS delivery Monitoring of course scheduling and delivery; tutor experiences via qualitative evaluation
after cohort 4
*Also measured weeks 10 and 18, 4 weeks either side of consolidation session 7.
†Variables combined using algorithm to form DAS2855 measured at weeks 0 and 26 only as necessitates hospital visit.
RAFT, Reducing Arthritis Fatigue by clinical Teams.
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acceptability curve, and one-way sensitivity analyses used
to judge potential impact of other sources of
uncertainty.
Analysis of tutor experiences: An inductive thematic
approach will identify themes grounded in the partici-
pants’ data.70 After reading and re-reading the anon-
ymised transcripts, signiﬁcant statements will be
extracted, coded, explored for links, built into overarch-
ing themes, and exempliﬁed by participants’ quotations.
A second qualitative researcher will independently
analyse a subset of the transcripts and themes compared
and agreed. The focus group and the interview ﬁndings
will be integrated to provide a comprehensive account
of tutors’ experiences.
ETHICS AND DISSEMINATION
Ethics: Patients will receive a detailed information sheet,
and research nurses obtaining written consent will be
trained in Good Clinical Practice. Patients may decline
to participate, or withdraw at any time without affecting
their clinical care, which will continue as normal during
the trial. On the basis of the original RCT, no serious
adverse events related to the intervention are antici-
pated, but any events will be reported in accordance
with the sponsoring Trust’s policy.
Research governance: The trial is sponsored by University
Hospitals Bristol NHS Foundation Trust (ie, covered by
NHS indemnity), managed by the RAFT central study
team and supported by a Trial Management Group, TSC
and DMEC. Data will be collected and retained in
accordance with the Data Protection Act 1998 and anon-
ymised during data entry. Study documents (paper and
electronic) will be retained in a secure location for
5 years after trial completion.
Patient and Public Involvement: Two patient research
partners (Robinson, Rooke), participants in the original
RCT, are coapplicants and members of the Trial
Management Group. They contributed to proposal
development, particularly in elucidating the appropriate
outcomes to assess questionnaire packages, information
sheets and recruitment practicalities. They will help
deliver tutor training, support interpretation of ﬁndings,
and advise on implementation.
Dissemination and implementation: Dissemination to the
clinical and academic community will be by academic
papers, conference presentations and submission to
NICE guidelines; to participants through a RAFT news-
letter, and to the wider RA population through the
National RA Society website and posters in the partici-
pating centres. The trainers’ experiences and supervi-
sion observations, and the qualitative evaluation with the
tutors, will inform RAFT manual and training reﬁne-
ment, and practical methods of widespread implementa-
tion of RAFT across rheumatology (eg, training DVDs).
RAFT training and materials will be subject to copyright
and an appropriate royalty-free licensing regimen to
maintain integrity.
DISCUSSION
Self-management of LTCs is a key government target, and
while CBT interventions for fatigue are successful, they
cannot be implemented in routine clinical care due to a
shortage of clinical psychologists or CB therapists in
usual clinical teams. However, in complex LTCs, nurses
and occupational therapists have an understanding of
the interactions between patients’ multiple and ﬂuctuat-
ing symptoms, disease activity, and lifestyle. Clinical teams
are thus well placed to deliver such an intervention, if
they can be provided with skills in basic CB approaches
and group management, and the materials needed to
deliver the course. Many good interventions fail to trans-
late from promising RCT data to clinical implementation
because of practicalities. This current study’s approach of
skilling-up clinical teams has implications for facilitating
interventions that can be delivered widely across the NHS
in a cost-effective manner, and the principle could be
applied to other symptoms in many LTCs. This trial is in
progress and recruiting to time ( June 2015, 22/28
planned CB courses randomised).
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